A dual GIP/GLP-1 receptor agonist examined in human metabolic studies.
Tirzepatide is a peptide that acts on GIP and GLP-1 receptors, which respond to gut-hormone signals. Human studies examine body-weight and metabolic responses in defined study populations.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
Reviewed 2026-10-26
Human — randomized phase 3 trial
2,539 adults with obesity or overweight; diabetes was excluded.
GIP/GLP-1 receptor agonism was studied over 72 weeks; weight reductions were greater than with placebo.
Gastrointestinal events were common and some participants discontinued treatment because of adverse events. Results do not validate a research vial.
PMID 35658024. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Identity search; no unambiguous compound record assigned to this listing. Check forms and synonyms carefully.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govReviewed human GLP1R record verified via UniProt API. This is a receptor record, not compound identity or evidence of vial activity.
UniProt — human GLP-1 receptorEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Tirzepatide is a peptide that acts on GIP and GLP-1 receptors, which respond to gut-hormone signals. Human studies examine body-weight and metabolic responses in defined study populations.
The Tirzepatide profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Tirzepatide: SURMOUNT-1 (2022): Human — randomized phase 3 trial
Publication: Tirzepatide: SURMOUNT-1Tirzepatide: SURMOUNT-1 (2022): 2,539 adults with obesity or overweight; diabetes was excluded.
Publication: Tirzepatide: SURMOUNT-1The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
Tirzepatide: SURMOUNT-1 (2022): Gastrointestinal events were common and some participants discontinued treatment because of adverse events. Results do not validate a research vial.
Publication: Tirzepatide: SURMOUNT-1These studies do not establish the identity, purity, safety or effects of the MXC Tirzepatide vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.